Kezar Life Sciences Reports Voluntarily Cessation Enrollment And Dosing In Phase 2b PALIZADE Trial Of Zetomipzomib In Active Lupus Nephritis Patients
Portfolio Pulse from Benzinga Newsdesk
Kezar Life Sciences has voluntarily stopped enrollment and dosing in its Phase 2b PALIZADE trial of Zetomipzomib for active lupus nephritis patients. This decision could impact the company's stock performance.
September 30, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Kezar Life Sciences has voluntarily ceased enrollment and dosing in its Phase 2b trial of Zetomipzomib for lupus nephritis. This could lead to negative investor sentiment and impact the stock price.
The voluntary cessation of a clinical trial can be perceived negatively by investors, as it may indicate issues with the drug's efficacy or safety. This could lead to a decrease in investor confidence and a potential drop in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100